SAN DIEGO, May 29, 2015 – ProSciento Inc., an clinical research organization (CRO) focused on diabetes, obesity and NAFLD/NASH, will present study results at next week’s American Diabetes Association (ADA) 75th Scientific Sessions, June 5 – 9 in Boston, Massachusetts.
Poster and oral presentations co-authored by Profil Institute scientists include:
Unique Profile of the Weekly Insulin Hm12470: Very Slow Onset of Action, Rapid Off-Rate Similar to Insulin, and Absence of Insulin Receptor Downregulation (96-OR)
Once-Weekly Combination of GLP-1R Agonist and Insulin (HM14220) Offers Improved Glycemic Control and Reduced Weight Gain Risk (172-OR)
LAPS GLP/GCG Dual Agonist, HM12525A, Confirmed Prolonged Pharmacokinetics in Healthy Volunteers: A First-in-Human Phase 1 Study (173-OR)
Dose-Response Improvements in Glycemic Control and Body Weight Reductions with HM11260C, a Once-Weekly GLP-1 Receptor Agonist with Liraglutide as Reference, in Type 2 Diabetes (T2DM) (278-OR)
Postmeal Glycemia following U-400 Ultra-Rapid-Acting/Basal Insulin BIOD-531 vs. Premixed and U-500 Insulins in Patients with Type 2 Diabetes (977-P)
A Single Dose Euglycemic Clamp Study in Healthy Subjects Demonstrating Pharmacokinetic and Pharmacodynamic Equivalence between MK-1293 and Lantus (1026-P)
Superagonistic Mechanism of Increased Glucodynamic and Weight Loss Effects of LAPSCA-Exendin-4 (HM11260C) (1116-P)
Potent Weight Loss Mechanism of the Novel Long-Acting GLP-1/Glucagon Dual Receptor Agonist (HM12525A) (1118-P)
LAPS-Exendin-4 (HM11260C) Significantly Enhances Insulin Secretion and ß-Cell Responsiveness in Subjects with Type 2 Diabetes Mellitus (T2DM) (1123-P)
Pharmacokinetic (PK) and Pharmacodynamic (PD) Modeling Predict Similar Dosing Frequencies for U-400 Ultra-Rapid-Acting Insulin BIOD-531 vs. Marketed Prandial-Basal Insulins (2531-PO)
Noninferior Delay in Gastric Emptying vs. Liraglutide and Favorable Glucometabolic Profile following Treatment with LAPSExendin-4 (HM11260C) in Subjects with Type 2 Diabetes Mellitus (T2DM) (2561-PO)
Once-a-Month Treatment with HM11260C Improves Glycemic Control in Type 2 Diabetes (T2DM)—Interim Data from a 16-Week Study (105-LB)
Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of BIOD-961 Compared with Marketed Glucagons (2-LB)
Ultra-Rapid-Acting/Basal Concentrated Insulin BIOD-531 Demonstrates Superior Postprandial Glucose Control and Potential for Flexible Post-meal Dosing Compared with Marketed Prandial/Basal Insulins in Insulin-Resistant Patients with Type 2 Diabetes (92-LB )
Significant Effects of HM11260C on Body Weight over 20 Weeks in Obese Subjects without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study (303-LB)
Moderator (3CT-PT09)
Development in Basal Insulin, Guided Audio Poster Tour, Moderator: Dr. Marcus Hompesch, CEO and President, ProSciento, Inc
About ProSciento, Inc.
ProSciento is a metabolism-focused, full scope clinical R&D services provider, with a mission to advance the global development of novel therapeutics for diabetes, NASH and obesity. The company is widely recognized for quality and scientific excellence, an unparalleled methodological toolkit, and extensive experience with virtually all metabolic drug and device classes. Utilizing its scalable R&D services model – combining deep therapeutic area expertise, strategic planning, an unparalleled methodological tool kit, and operational execution from late preclinical to phase III readiness – ProSciento provides highly customizable services for its global client base in today’s rapidly evolving landscape of metabolic drug and device development. For more information, please visit www.prosciento.com.
For media inquiries, please contact:
Abby Devine
Senior Director, Corporate Communications, ProSciento, Inc.
Tel: +1 858 663-6148
abby.devine@prosciento.com
For business development inquires:
bd@prosciento.com
For clinical study enrollment inquires:
Tel: +1 (866) 308-7427
volunteer@prosciento.com
